Combustion-Generated EPFRs: Assessing Cardiovascular Risks of Exposure
燃烧产生的 EPFR:评估暴露的心血管风险
基本信息
- 批准号:10341193
- 负责人:
- 金额:$ 28.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-15 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAgonistAirAirborne Particulate MatterAlveolarArchivesAryl Hydrocarbon ReceptorBindingBiological MarkersBloodBlood PressureBlood VesselsCardiacCardiopulmonaryCardiovascular DiseasesCardiovascular systemCathetersCollaborationsCommunitiesComplementDataData AnalysesDevelopmentDevicesEndothelial CellsEndotheliumEpithelialEpithelial CellsExposure toFree RadicalsFunctional disorderHazardous WasteHealthHeartHeart DiseasesHistologyIndustrializationInhalationInhalation ExposureInhalation ToxicologyInjuryKnowledgeLeftLeft Ventricular FunctionLigandsLinkLipidsLungMass Spectrum AnalysisMeasuresMediatingMediator of activation proteinMembraneMembrane LipidsModelingMorphologyMusMyocardial dysfunctionOxidation-ReductionOxidative StressOxidesParticulate MatterPhysiologic intraventricular pressurePhysiologicalPlayPulmonary Vascular ResistanceReactive Oxygen SpeciesReceptor ActivationResearchRiskRisk AssessmentRodentRoleSecondary toSignal Recognition ParticleSiteSoilSourceSuperfundSystemTechnologyTelemetryTestingTissuesToxic effectVascular DiseasesVentricularWorkair filteralveolar epitheliumaryl hydrocarbon receptor ligandbiological systemsbody systemcardiovascular risk factordata managementdesignendothelial dysfunctionenvironmental chemistryepidemiologic datafree radical oxygenheart functionlung pressuremortalitynoveloxidationoxidized lipidparticlepollutantpressurepulmonary arterial pressureresponsesmall moleculesuperfund siteuptakevascular injuryweb portal
项目摘要
Project Summary/Abstract: Project 2
Particulate matter (PM) is consistently associated with cardiopulmonary and cardiovascular mortality. Despite
the risk of exposure, little is known about the mechanisms underlying PM-mediated toxicity. Our Center has
shown that PM emissions from the thermal treatment (TT) of hazardous organics or contaminated soils at
Superfund sites produce environmentally persistent free radicals (EPFRs). EPFRs are a unique particle-
pollutant system capable of redox cycling to generate reactive oxygen species (ROS) in biological systems.
EPFRs are present in contaminated Superfund soils and airborne PM near industrialized Superfund sites. Our
prior Superfund project focused on the role of EPFRs in modulating cardiac function and disease. Although
inhalation of EPFRs decreased baseline cardiac function, we found that these effects were secondary to
changes in pulmonary vascular resistance. The mechanism(s) underlying these vascular effects are unknown;
however, our preliminary data suggest that EPFR-mediated activation of the aryl hydrocarbon receptor (AhR)
in pulmonary epithelial cells resulting in the release of vasoactive factors may play an important
pathophysiological role. Our central hypothesis is that EPFR-mediated activation of AhR at the air-blood
interface and mobilization of vasoactive mediators leads to activation/dysfunction of the pulmonary and
systemic vasculature, resulting in cardiovascular disease. To test this hypothesis, Specific Aim 1 will test
whether EPFR-mediated activation of the AhR in lung epithelium is responsible for the increase in pulmonary
pressure and decreased diastolic filling that underlies EPFR induced cardiac dysfunction. After establishing the
vasculature as the locus of injury, Specific Aim 2 will elucidate the cellular mechanisms of vascular injury by
testing whether EPFRs induce vascular dysfunction via activation of the AhR. In both aims, control littermate
mice and mice deficient in AhR specifically in alveolar type II will be exposed subchronially to EPFRs, non-
EPFR PM, or filtered air using a recently designed inhalation system. Millar pressure-volume catheters will be
used to measure left ventricular function and pulmonary arterial pressure in exposed mice. Telemetry devices
will be used to record blood pressure. Endothelium-dependent vascular reactivity, as well as markers for both
endothelial dysfunction and activation, will be assessed. Specific Aim 3 will identify a putative ligand promoting
EPFR-induced AhR activation and test whether this metabolite is associated with EPFR-mediated vascular
dysfunction. In collaboration with Project 1, this aim will use novel mass spectrometry approaches to identify
and characterize EPFR-induced lipid oxidation products that may serve as endogenous AhR agonists so that
we may correlate tissue and blood levels of these metabolites with vascular dysfunction. Completion of these
Aims will provide important new data linking EPFR-mediated oxidative stress in epithelial cells, AhR activation,
and cardiovascular disease. This information is critical for assessing risks to those living in proximity to sites
using TT technologies to remediate Superfund or other hazardous wastes.
项目概要/摘要:项目2
颗粒物(PM)始终与心肺和心血管死亡率相关。尽管
暴露的风险,鲜为人知的机制PM介导的毒性。我中心
表明,有害有机物或污染土壤的热处理(TT)产生的PM排放,
超级基金的网站产生环境持久性自由基(EPFRs)。EPFR是一种独特的粒子-
在生物系统中能够氧化还原循环以产生活性氧(ROS)的污染物系统。
EPFR存在于污染的超级基金土壤和空气中的PM附近的工业化超级基金网站。我们
先前的超级基金项目集中于EPFR在调节心脏功能和疾病中的作用。虽然
吸入EPFR降低了基线心功能,我们发现这些影响是继发于
肺血管阻力的变化。这些血管效应的潜在机制尚不清楚;
然而,我们初步数据表明,EPFR介导的芳香烃受体(AhR)激活
在肺上皮细胞中导致血管活性因子的释放可能起重要作用
病理生理作用我们的中心假设是EPFR介导的AhR在气-血
血管活性介质的界面和动员导致肺和肺动脉的激活/功能障碍,
全身血管系统,导致心血管疾病。为了检验这一假设,具体目标1将检验
EPFR介导的肺上皮AhR激活是否是肺上皮细胞中
压力和舒张期充盈减少是EPFR诱导的心功能不全的基础。在建立
血管作为损伤的位点,具体目标2将阐明血管损伤的细胞机制,
测试EPFR是否通过激活AhR诱导血管功能障碍。在这两个目标中,控制同窝仔
小鼠和肺泡II型AhR特异性缺陷的小鼠将亚慢性暴露于EPFR,
EPFR PM,或使用最近设计的吸入系统过滤的空气。Millar压力容积导管将
用于测量暴露小鼠的左心室功能和肺动脉压。遥测装置
将被用来记录血压。内皮依赖性血管反应性以及两者的标志物
将评估内皮功能障碍和活化。具体目标3将确定一个推定的配体促进
EPFR诱导的AhR激活,并测试该代谢产物是否与EPFR介导的血管生成相关。
功能障碍与项目1合作,该目标将使用新的质谱方法来识别
并表征EPFR诱导的脂质氧化产物,其可用作内源性AhR激动剂,
我们可以将这些代谢物的组织和血液水平与血管功能障碍联系起来。完成这些
目标将提供重要的新数据,将EPFR介导的上皮细胞氧化应激、AhR激活,
和心血管疾病。这一信息对于评估居住在现场附近的人所面临的风险至关重要
利用TT技术对超级基金或其他危险废物进行补救。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TAMMY R DUGAS其他文献
TAMMY R DUGAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TAMMY R DUGAS', 18)}}的其他基金
Novel coatings releasing synergistic polyphenols promote vascular healing
新型涂层释放协同多酚促进血管愈合
- 批准号:
8716232 - 财政年份:2014
- 资助金额:
$ 28.87万 - 项目类别:
Novel coatings releasing synergistic polyphenols promote vascular healing
新型涂层释放协同多酚促进血管愈合
- 批准号:
8918078 - 财政年份:2014
- 资助金额:
$ 28.87万 - 项目类别:
Research Experience and Training Coordination Core (RETCC)
研究经验和培训协调核心(RETCC)
- 批准号:
10341189 - 财政年份:2009
- 资助金额:
$ 28.87万 - 项目类别:
Combustion-Generated EPFRs: Assessing Cardiovascular Risks of Exposure
燃烧产生的 EPFR:评估暴露的心血管风险
- 批准号:
10576461 - 财政年份:2009
- 资助金额:
$ 28.87万 - 项目类别:
Antiretroviral Therapy, Endothelial Dysfunction and Atherosclerosis
抗逆转录病毒治疗、内皮功能障碍和动脉粥样硬化
- 批准号:
7838921 - 财政年份:2009
- 资助金额:
$ 28.87万 - 项目类别:
Research Experience and Training Coordination Core (RETCC)
研究经验和培训协调核心(RETCC)
- 批准号:
10576457 - 财政年份:2009
- 资助金额:
$ 28.87万 - 项目类别:
Combustion-Generated EPFRs: Assessing Cardiovascular Risks of Exposure
燃烧产生的 EPFR:评估暴露的心血管风险
- 批准号:
10116407 - 财政年份:2009
- 资助金额:
$ 28.87万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 28.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 28.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)